KRE ALKALYN 120 CAPSULES 820 mg
Food supplement declared in France, declaration No 2019-1-572, decision dated 21 January 2019
KRE ALKALYN 120 CAPSULES 820 mg (HX NUTRITION) is a food supplement declared in France. Status: declared in France, may be marketed. Main ingredients: Monohydrate de créatine. 1 point in its composition requires a check (prohibited substance, dose or novel food).
- Brand
- HX NUTRITION
- Food business operator placing the product on the market
- LABORATORIOS FERQUISA SA
- Status
- Declared in France, may be marketed: the authorities did not object to the declaration (this is neither an authorisation nor a safety assessment)
- Form
- Capsule
- Daily dose
- 3 Capsules
- Directions for use
- Prendre 3 capsules par jour avant l'entraînement
Declaration 293218, procedure Article 15. Compl'Alim, food supplement declarations (France), retrieved 15 November 2026.
Declared composition
Other active ingredients
| Name | Per day |
|---|---|
| Monohydrate de créatine | not declared |
Additives
E132, E171, E470b, E551
Other ingredients
maltodextrine, gélatine
List from the declaration, administrative decision dated (Compl'Alim, food supplement declarations (France)).
Label warnings
Voir les avertissements sur l'étiquette
Regulatory points
- À vérifier
The composition lists additive E171 (titanium dioxide), removed from the list of additives allowed in food, supplements included: since 7 August 2022, a supplement containing it can no longer be placed on the market in the Union. The declaration predates this removal: if the product is still sold, its formula must have changed; check the label.
Source: Regulation (EU) 2022/63: titanium dioxide (E171) removed from the food additives allowed in the EU, règlement (UE) 2022/63.
This information reproduces the manufacturer's declaration to the administration (DGAL). It does not say whether the product is effective and does not replace advice from a doctor or pharmacist, particularly during pregnancy or when taking medication.
Official warnings (Health Canada)
Health Canada publishes warnings on these ingredients:
- Monohydrate de créatine
Read the warning, when it applies and the studies cited
Creatine Monohydrate
Route of administration: Oral
Cautions and warnings
When using this product you may gain weight (Volek and Rawson 2004; Bemben et al. 2001; Mihic et al. 2000).
Sources cited by Health Canada (3)
- Bemben MG, Bemben DA, Loftiss DD, Knehans AW. 2001. Creatine supplementation during resistance training in college football athletes. Medicine & Science in Sports & Exercise 33(10):1667-1673.
- Mihic S, MacDonald JR, McKenzie S, Tarnopolsky MA. 2000. Acute creatine loading increases fat-free mass, but does not affect blood pressure, plasma creatinine, or CK activity in men and women. Medicine & Science in Sports and Exercise 32(2):291-296.
- Volek JS, Rawson ES. 2004. Scientific basis and practical aspects of creatine supplementation for athletes. Nutrition 20(7-8):609-614.
Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are pregnant or breastfeeding.
Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you have a kidney disorder (Pline and Smith 2005; Pritchard and Kalra 1998).
Sources cited by Health Canada (2)
- Pline KA, Smith CL. 2005. The effect of creatine intake on renal function. The Annals of Pharmacotherapy 39(6):1093-1096.
- Pritchard NR, Kalra PA. 1998. Renal dysfunction accompanying oral creatine supplements. The Lancet 351(9111):1252-1253.
They concern the ingredient, not this product or its dose. They do not replace medical advice.
Brand : HX NUTRITION
Is something on this product wrong or out of date, whether you are a reader or the brand? Write to contact@compoatlas.com: every correction is published in the corrections log.
Cite this page: CompoAtlas, “KRE ALKALYN 120 CAPSULES 820 mg (HX NUTRITION): composition and regulation”, https://compoatlas.com/en/supplements/products/293218-kre-alkalyn-120-capsules-820-mg, updated 15 November 2026.